Deciphera Pharmaceuticals Llc Stock Current Liabilities
Deciphera Pharmaceuticals LLC fundamentals help investors to digest information that contributes to Deciphera Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Deciphera Stock. The fundamental analysis module provides a way to measure Deciphera Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Deciphera Pharmaceuticals stock.
Deciphera |
Deciphera Pharmaceuticals LLC Company Current Liabilities Analysis
Deciphera Pharmaceuticals' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Deciphera Pharmaceuticals Current Liabilities | 5.98 M |
Most of Deciphera Pharmaceuticals' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Deciphera Pharmaceuticals LLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, Deciphera Pharmaceuticals LLC has a Current Liabilities of 5.98 M. This is 99.66% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current liabilities for all United States stocks is 99.92% higher than that of the company.
Deciphera Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Deciphera Pharmaceuticals' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Deciphera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Deciphera Pharmaceuticals by comparing valuation metrics of similar companies.Deciphera Pharmaceuticals is currently under evaluation in current liabilities category among its peers.
Deciphera Fundamentals
| Return On Equity | -0.5 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (1.09) % | |||
| Operating Margin | (1.09) % | |||
| Current Valuation | 1.97 B | |||
| Shares Outstanding | 86.48 M | |||
| Shares Owned By Insiders | 28.48 % | |||
| Shares Owned By Institutions | 72.03 % | |||
| Number Of Shares Shorted | 3.92 M | |||
| Price To Earning | (6.78) X | |||
| Price To Book | 7.00 X | |||
| Price To Sales | 12.65 X | |||
| Revenue | 163.36 M | |||
| Gross Profit | (62.55 M) | |||
| EBITDA | (210.96 M) | |||
| Net Income | (194.94 M) | |||
| Cash And Equivalents | 383.85 M | |||
| Cash Per Share | 5.74 X | |||
| Total Debt | 25.88 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 6.02 X | |||
| Book Value Per Share | 3.85 X | |||
| Cash Flow From Operations | (146.7 M) | |||
| Short Ratio | 1.05 X | |||
| Earnings Per Share | (2.21) X | |||
| Price To Earnings To Growth | (0.32) X | |||
| Target Price | 27.52 | |||
| Number Of Employees | 355 | |||
| Beta | 0.18 | |||
| Market Capitalization | 2.21 B | |||
| Total Asset | 473.57 M | |||
| Retained Earnings | (1.43 B) | |||
| Working Capital | 280.82 M | |||
| Current Asset | 70.55 M | |||
| Current Liabilities | 5.98 M | |||
| Net Asset | 473.57 M |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Deciphera Stock
If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |